Jounce Therapeutics, Inc.
News
Jounce Therapeutics (NASDAQ:JNCE) & Kymera Therapeutics (NASDAQ:KYMR) Head to Head Comparison
Zolmax Jounce Therapeutics (NASDAQ:JNCE Get Rating) and Kymera Therapeutics (NASDAQ:KYMR Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, ...\n more…
StockNews.com Initiates Coverage on Jounce Therapeutics (NASDAQ:JNCE)
Ticker Report Investment analysts at StockNews.com started coverage on shares of Jounce Therapeutics (NASDAQ:JNCE Get Rating) in a report issued on Thursday. The firm set a hold rating on the stock. Other analysts have also recently issued research reports about the stock. Raymond James cut ...\n more…
Jounce Therapeutics (NASDAQ:JNCE) Research Coverage Started at StockNews.com
Zolmax StockNews.com began coverage on shares of Jounce Therapeutics (NASDAQ:JNCE Get Rating) in a report released on Thursday morning. The firm issued a hold rating on the stock. Other analysts have also issued reports about the company. Raymond James lowered Jounce Therapeutics from an outperform rating ...\n more…
StockNews.com Initiates Coverage on Jounce Therapeutics (NASDAQ:JNCE)
Ticker Report Stock analysts at StockNews.com began coverage on shares of Jounce Therapeutics (NASDAQ:JNCE Get Rating) in a research note issued on Wednesday. The brokerage set a hold rating on the stock. Several other research analysts have also recently commented on JNCE. Raymond James cut...\n more…
Jounce Therapeutics (NASDAQ:JNCE) Earns Hold Rating from Analysts at StockNews.com
Zolmax StockNews.com initiated coverage on shares of Jounce Therapeutics (NASDAQ:JNCE Get Rating) in a report issued on Wednesday morning. The brokerage issued a hold rating on the stock. JNCE has been the subject of several other research reports. Piper Sandler downgraded shares of Jounce Therapeutics ...\n more…
Jounce Therapeutics (NASDAQ:JNCE) Coverage Initiated at StockNews.com
Zolmax StockNews.com initiated coverage on shares of Jounce Therapeutics (NASDAQ:JNCE Get Rating) in a research report released on Tuesday . The brokerage issued a hold rating on the stock. Several other equities analysts have also weighed in on the stock. Piper Sandler lowered shares of Jounce ...\n more…